GATC Biotech

GATC Biotech, located in Constance (Germany) with a subsidiary in Cambridge (UK), is a leading provider of molecular biological services and innovative bioinformatics solutions for industry and academia worldwide. Today, GATC has 37 employees and serves 3000 customers in 40 countries. This year GATC celebrates its 15th anniversary. Most of GATC‘s employees are scientists with long-term experience in biotechnology and molecular biology. GATC is privately owned and profitable since its foundation in 1990. The company is ISO-certified (ISO 9001:2000).

GATC‘s business is based on a developing trend to outscourcing. Industry and academia increasingly entrust biomolecular projects to external service providers who carry out these projects quickly, efficiently and economically.

GATC Biotech is the only European bioscientific service provider able to accomplish projects that span the fields of genomics (DNA), transcriptomics (RNA/cDNA), functional analysis (analysis of protein expression/function) and bioinformatics (service & software).

Since 1991 GATC has been a partner for industry and the European Union in sequencing genomes, e.g. Saccharomyces cerevisiae, Arabidopsis thaliana, Leishmania major or Aspergillus niger.

GATC distributes and supports all software products (e.g. LasergeneTM) of DNASTAR, Inc. Madison, WI USA, GeneMarker, Mutation Surveyor, Mutation Explorer of SoftGenetics, LLC. State College, PA USA and ERGOTM, the bioinformatic suite of Integrated Genomics, Inc. Chicago, IL USA.

GATC is a cooperation partner in a number of research projects, e.g. with

  • the Hebrew University of Jerusalem for the development and optimisation of a bio-insecticide based on natural occurring toxins
  • the Frauenhofer Institute for Interfacial Engineering and Biotechnology together with the Laboratory for Functional Genome Analysis (LAFUGA) of the Ludwig Maximilians University in Munich to develop a method for the identification and characterisation of tissue-specific gene expression

GATC Biotech is taking part in an EU funded research project to evaluate the safety of gene therapy in the treatment of monogenic inherited deseases, such as immunodeficiencies, hemoglobinopathies, anemias and storage disorders. Other contributors to the project comprise 18 academic groups and 3 companies from 9 European countries. The aim of the research project is an unbiased safety and efficiency evaluation of retroviral transgenesis for gene therapy of inherited deseases. Central aspects of this evaluation are the molecular and clinical monitoring of model studies for genetic therapies as well as molecular studies in cell culture systems and animal models. The results will generate the basis for technology developments that enhance the safety of retroviral gene therapy.

Peter Pohl, CEO: “We don‘t sell products, we only do what matters to the customer. We invest in our customers to get to know them and understand their research problems and then provide the best solution. We always ask ourselves how best to serve the customer. It‘s what we do on a daily basis.“